Recently, production of anti‐human ASCT2 mAbs was reported, and these mAbs suppressed glutamine‐dependent cancer cell growth.51 However, it remains unclear whether these mAbs have in vivo anti‐tumor activity against KRAS‐mutated cancers. This evidence concerns the gene KRAS and neoplasm.